Renalytix Plc (LON:RENX – Get Free Report) was down 4% during trading on Tuesday . The stock traded as low as GBX 6 and last traded at GBX 6. Approximately 786,437 shares were traded during trading, an increase of 84% from the average daily volume of 428,139 shares. The stock had previously closed at GBX 6.25.
Renalytix Stock Performance
The stock has a market capitalization of £26.23 million, a price-to-earnings ratio of -0.86 and a beta of 2.10. The company has a 50 day simple moving average of GBX 6.36 and a 200-day simple moving average of GBX 7.08. The company has a quick ratio of 2.42, a current ratio of 0.24 and a debt-to-equity ratio of -72.91.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
See Also
- Five stocks we like better than Renalytix
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
